{"id":"duloxetine-hydrochloride-enteric-coated-capsules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dry mouth"},{"rate":"10-20%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Duloxetine hydrochloride acts by inhibiting the reuptake of serotonin and norepinephrine, increasing their concentrations in the synaptic cleft and enhancing neurotransmission.","oneSentence":"Selective serotonin and norepinephrine reuptake inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:35:53.309Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Diabetic peripheral neuropathic pain"}]},"trialDetails":[{"nctId":"NCT06842992","phase":"PHASE2","title":"A Phase II Study to Evaluate NH102 for Depression","status":"COMPLETED","sponsor":"Jiangsu Nhwa Pharmaceutical Co., Ltd.","startDate":"2024-12-04","conditions":"Major Depressive Disorder (MDD)","enrollment":243},{"nctId":"NCT06259526","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression","status":"COMPLETED","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2023-12-26","conditions":"Depression","enrollment":267},{"nctId":"NCT04364997","phase":"PHASE3","title":"Study of Desvenlafaxine in Treating Major Depressive Disorder.","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-06-18","conditions":"Major Depressive Disorder","enrollment":420},{"nctId":"NCT05018013","phase":"PHASE2","title":"Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-08-21","conditions":"Major Depressive Disorder (MDD)","enrollment":240},{"nctId":"NCT04751318","phase":"PHASE1","title":"Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2021-02-27","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT04723238","phase":"PHASE1","title":"Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2021-01-23","conditions":"Bioequivalence","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Duloxetine"],"phase":"phase_2","status":"active","brandName":"Duloxetine hydrochloride enteric-coated capsules","genericName":"Duloxetine hydrochloride enteric-coated capsules","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selective serotonin and norepinephrine reuptake inhibitor Used for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}